1. Home
  2. Labeler Index
  3. Avyxa Pharma, Llc
  4. 83831-103
  5. Product Images: Docivyx

Product Images Docivyx

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Docetaxel-Structure - 2ad4f265 675e 47bf a2fa 57d9266a6dda 01
  2. Figure 1: TAX316 Disease-Free Survival K-M curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 02
  3. Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 03
  4. Figure 3: TAX317 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Best Supportive Care - 2ad4f265 675e 47bf a2fa 57d9266a6dda 04
  5. Figure 4: TAX320 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Vinorelbine or Ifosfamide Control - 2ad4f265 675e 47bf a2fa 57d9266a6dda 05
  6. Figure 5: TAX327 Survival K-M Curves - 2ad4f265 675e 47bf a2fa 57d9266a6dda 06
  7. Figure 6: Gastric Cancer Study (TAX325) Time to Progression K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 07
  8. Figure 7: Gastric Cancer Study (TAX325) Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 08
  9. Figure 8: TAX323 Progression-Free Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 09
  10. Figure 9: TAX323 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 10
  11. Figure 10: TAX324 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 11
  12. DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 12
  13. DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 13
  14. DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 14
  15. DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 15
  16. DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 16
  17. DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 17
  18. Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 187 2
  19. Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 213 2

Product Label Images

The following 19 images provide visual information about the product associated with Docivyx NDC 83831-103 by Avyxa Pharma, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Docetaxel-Structure - 2ad4f265 675e 47bf a2fa 57d9266a6dda 01

Docetaxel-Structure - 2ad4f265 675e 47bf a2fa 57d9266a6dda 01

Figure 1: TAX316 Disease-Free Survival K-M curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 02

Figure 1: TAX316 Disease-Free Survival K-M curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 02

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 03

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 03

Figure 3: TAX317 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Best Supportive Care - 2ad4f265 675e 47bf a2fa 57d9266a6dda 04

Figure 3: TAX317 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Best Supportive Care - 2ad4f265 675e 47bf a2fa 57d9266a6dda 04

This text provides information on cumulative probability related to survival time in months. The log-rank p-value is reported as 0.010, indicating a significant difference.*

Figure 4: TAX320 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Vinorelbine or Ifosfamide Control - 2ad4f265 675e 47bf a2fa 57d9266a6dda 05

Figure 4: TAX320 Survival K-M Curves - DOCIVYX 75 mg/m2 Versus Vinorelbine or Ifosfamide Control - 2ad4f265 675e 47bf a2fa 57d9266a6dda 05

This information presents the cumulative probability of overall survival at different time points (3, 6, 9, 12, 15, and 18 months) as well as the Log-rank p-value (0.13) for comparison.*

Figure 5: TAX327 Survival K-M Curves - 2ad4f265 675e 47bf a2fa 57d9266a6dda 06

Figure 5: TAX327 Survival K-M Curves - 2ad4f265 675e 47bf a2fa 57d9266a6dda 06

Survival probability based on survival time in months (9, 12, 15, 18, 21) is provided in the data. The corresponding survival time in months seems to be 24, 27, and 30.*

Figure 6: Gastric Cancer Study (TAX325) Time to Progression K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 07

Figure 6: Gastric Cancer Study (TAX325) Time to Progression K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 07

Figure 7: Gastric Cancer Study (TAX325) Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 08

Figure 7: Gastric Cancer Study (TAX325) Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 08

This data provides the survival probability in percentage at different survival times measured in months. The table shows the chances of survival at 15, 18, 21, 24, and 27 months.*

Figure 8: TAX323 Progression-Free Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 09

Figure 8: TAX323 Progression-Free Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 09

Progression Free Survival Probability (%) for different time points (in months).*

Figure 9: TAX323 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 10

Figure 9: TAX323 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 10

Figure 10: TAX324 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 11

Figure 10: TAX324 Overall Survival K-M Curve - 2ad4f265 675e 47bf a2fa 57d9266a6dda 11

This text appears to be a table showing survival probabilities over time for two treatment groups (TPF and PF) along with the number of patients at risk and survival time in months for each time point. The data presented includes survival probability percentages, number of patients at risk, and survival time in months. This information could be useful for analyzing and comparing the effectiveness of the two treatments over time.*

DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 12

DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 12

This is the product information for Docetaxel Injection, which comes in a 20 mg per 2 mL (10 mg per mL) single-dose vial for intravenous infusion only. The National Drug Code (NDC) for this product is 83831-101-02. It is recommended to discard any unused portion of the medication.*

DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 13

DOCIVYX (docetaxel) Injection, 20 mg/2 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 13

This text is a description of Docivyx (Docetaxel) Injection, a medication that is ready to add to an infusion solution. It contains 10 mg of Docetaxel, 380 mg of SBECD, 160 mg of Polyethylene Glycol 300 NF, 40 mg of PVP Ky, and other ingredients. The recommended dosage should be followed as per prescribing information. It is a hazardous drug and should be kept out of reach of children, stored between 2°C to 25°C, and protected from light. The product is manufactured for Avyxa Pharma, LLC, USA, and is made in China. Each vial contains 20 mg per 2 mL and should be used for intravenous infusion only. Unused portions should be discarded.*

DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 14

DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 14

DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 15

DOCIVYX (docetaxel) Injection, 80 mg/8 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 15

This is a description of Docivyx (Docetaxel) Injection, a medication ready to be added to an infusion solution for intravenous infusion. Each mL contains 10 mg Docetaxel, 380 mg SBECD, 160 mg Polyethylene Glycol 300 NF, 40 mg PVP Kiz, 220 mg Dehydrated Alcohol USP, and Citric Acid Anhydrous USP. The recommended dosage should be followed as per prescribing information. It is important to keep this hazardous drug out of reach of children, and to store it between 2°C to 25°C (36°F to 77°F) while protecting it from light. The medication comes in an 8 mL single-dose vial that should be discarded if unused. The product is manufactured for Avyxa Pharma, LLC, in New Jersey, USA, and has been made in China. It includes NDC 83831-102-08 and J Code J9172.*

DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 16

DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Vial Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 16

DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 17

DOCIVYX (docetaxel) Injection, 160 mg/16 mL -Carton Label - 2ad4f265 675e 47bf a2fa 57d9266a6dda 17

This text appears to be related to a medication called "Docetaxel Injection". The medication is in a 16 mL single-dose vial and contains 10 mg of Docetaxel along with other components. It is intended for intravenous infusion and should be stored at temperatures between 2°C to 25°C. It is important to keep this hazardous drug out of reach of children and to discard any unused portion. The prescribing information should be referred to for recommended dosages.*

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 187 2

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 187 2

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 213 2

Image - 2ad4f265 675e 47bf a2fa 57d9266a6dda 213 2

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.